Targeting PD-L1 for Ischemic Stroke Recovery: Age-Dependent Modulation of Immune and BBB Pathways.

CNS Neurosci Ther · 2025 · PMC12287378 · PMID 40702766

Europe PMC DOI

hedged sentence

0.0753

closest p · 1.5× alpha

0.0753

boldest claim

The sentences

showed a trendp = 0.0753so close (0.05 < p ≤ 0.1)

The survival rates showed a trend toward improvement in the young PD‐L1 mAb‐treated group compared to aged mice ( p = 0.0753) (Figure 3B ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.